Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 170

1.

Anti-PCSK9 antibodies inhibit pro-atherogenic mechanisms in APOE*3Leiden.CETP mice.

Schuster S, Rubil S, Endres M, Princen HMG, Boeckel JN, Winter K, Werner C, Laufs U.

Sci Rep. 2019 Jul 31;9(1):11079. doi: 10.1038/s41598-019-47242-0.

2.

The APOE3-Leiden Heterozygous Glucokinase Knockout Mouse as Novel Translational Disease Model for Type 2 Diabetes, Dyslipidemia, and Diabetic Atherosclerosis.

Pouwer MG, Heinonen SE, Behrendt M, Andréasson AC, van Koppen A, Menke AL, Pieterman EJ, van den Hoek AM, Jukema JW, Leighton B, Jönsson-Rylander AC, Princen HMG.

J Diabetes Res. 2019 Feb 21;2019:9727952. doi: 10.1155/2019/9727952. eCollection 2019.

3.

Dose Effects of Ammonium Perfluorooctanoate on Lipoprotein Metabolism in APOE*3-Leiden.CETP Mice.

Pouwer MG, Pieterman EJ, Chang SC, Olsen GW, Caspers MPM, Verschuren L, Jukema JW, Princen HMG.

Toxicol Sci. 2019 Apr 1;168(2):519-534. doi: 10.1093/toxsci/kfz015.

4.

Inflammatory cytokine oncostatin M induces endothelial activation in macro- and microvascular endothelial cells and in APOE*3Leiden.CETP mice.

van Keulen D, Pouwer MG, Pasterkamp G, van Gool AJ, Sollewijn Gelpke MD, Princen HMG, Tempel D.

PLoS One. 2018 Oct 1;13(10):e0204911. doi: 10.1371/journal.pone.0204911. eCollection 2018.

5.

The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model.

Pouwer MG, Pieterman EJ, Verschuren L, Caspers MPM, Kluft C, Garcia RA, Aman J, Jukema JW, Princen HMG.

Front Cardiovasc Med. 2018 Jun 12;5:55. doi: 10.3389/fcvm.2018.00055. eCollection 2018.

6.

Results, meta-analysis and a first evaluation of UNOxR, the urinary nitrate-to-nitrite molar ratio, as a measure of nitrite reabsorption in experimental and clinical settings.

Tsikas D, Hanff E, Bollenbach A, Kruger R, Pham VV, Chobanyan-Jürgens K, Wedekind D, Arndt T, Jörns A, Berbée JFP, Princen HMG, Lücke T, Mariotti F, Huneau JF, Ückert S, Frölich JC, Lenzen S.

Amino Acids. 2018 Jul;50(7):799-821. doi: 10.1007/s00726-018-2573-z. Epub 2018 May 4.

PMID:
29728915
7.

Atorvastatin accelerates clearance of lipoprotein remnants generated by activated brown fat to further reduce hypercholesterolemia and atherosclerosis.

Hoeke G, Wang Y, van Dam AD, Mol IM, Gart E, Klop HG, van den Berg SM, Pieterman EH, Princen HMG, Groen AK, Rensen PCN, Berbée JFP, Boon MR.

Atherosclerosis. 2017 Dec;267:116-126. doi: 10.1016/j.atherosclerosis.2017.10.030. Epub 2017 Oct 26.

PMID:
29121499
8.

Variable cartilage degradation in mice with diet-induced metabolic dysfunction: food for thought.

Kozijn AE, Gierman LM, van der Ham F, Mulder P, Morrison MC, Kühnast S, van der Heijden RA, Stavro PM, van Koppen A, Pieterman EJ, van den Hoek AM, Kleemann R, Princen HMG, Mastbergen SC, Lafeber FPJG, Zuurmond AM, Bobeldijk I, Weinans H, Stoop R.

Osteoarthritis Cartilage. 2018 Jan;26(1):95-107. doi: 10.1016/j.joca.2017.10.010. Epub 2017 Oct 24.

9.

The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice.

Landlinger C, Pouwer MG, Juno C, van der Hoorn JWA, Pieterman EJ, Jukema JW, Staffler G, Princen HMG, Galabova G.

Eur Heart J. 2017 Aug 21;38(32):2499-2507. doi: 10.1093/eurheartj/ehx260.

10.

Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease.

Dewey FE, Gusarova V, Dunbar RL, O'Dushlaine C, Schurmann C, Gottesman O, McCarthy S, Van Hout CV, Bruse S, Dansky HM, Leader JB, Murray MF, Ritchie MD, Kirchner HL, Habegger L, Lopez A, Penn J, Zhao A, Shao W, Stahl N, Murphy AJ, Hamon S, Bouzelmat A, Zhang R, Shumel B, Pordy R, Gipe D, Herman GA, Sheu WHH, Lee IT, Liang KW, Guo X, Rotter JI, Chen YI, Kraus WE, Shah SH, Damrauer S, Small A, Rader DJ, Wulff AB, Nordestgaard BG, Tybjærg-Hansen A, van den Hoek AM, Princen HMG, Ledbetter DH, Carey DJ, Overton JD, Reid JG, Sasiela WJ, Banerjee P, Shuldiner AR, Borecki IB, Teslovich TM, Yancopoulos GD, Mellis SJ, Gromada J, Baras A.

N Engl J Med. 2017 Jul 20;377(3):211-221. doi: 10.1056/NEJMoa1612790. Epub 2017 May 24.

11.

Anacetrapib, but not evacetrapib, impairs endothelial function in CETP-transgenic mice in spite of marked HDL-C increase.

Simic B, Mocharla P, Crucet M, Osto E, Kratzer A, Stivala S, Kühnast S, Speer T, Doycheva P, Princen HM, van der Hoorn JW, Jukema JW, Giral H, Tailleux A, Landmesser U, Staels B, Lüscher TF.

Atherosclerosis. 2017 Feb;257:186-194. doi: 10.1016/j.atherosclerosis.2017.01.011. Epub 2017 Jan 16.

PMID:
28152406
12.

Comment on "Hypercholesterolemia with consumption of PFOA-laced Western diets is dependent on strain and sex of mice" by Rebholz S.L. et al. Toxicol. Rep. 2016 (3) 46-54.

Princen HMG, Pouwer MG, Pieterman EJ.

Toxicol Rep. 2016 Feb 11;3:306-309. doi: 10.1016/j.toxrep.2016.02.002. eCollection 2016. No abstract available.

13.

Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9.

van der Tuin SJ, Kühnast S, Berbée JF, Verschuren L, Pieterman EJ, Havekes LM, van der Hoorn JW, Rensen PC, Jukema JW, Princen HM, Willems van Dijk K, Wang Y.

J Lipid Res. 2015 Nov;56(11):2085-93. doi: 10.1194/jlr.M057794. Epub 2015 Sep 4.

14.

Salsalate attenuates diet induced non-alcoholic steatohepatitis in mice by decreasing lipogenic and inflammatory processes.

Liang W, Verschuren L, Mulder P, van der Hoorn JW, Verheij J, van Dam AD, Boon MR, Princen HM, Havekes LM, Kleemann R, van den Hoek AM.

Br J Pharmacol. 2015 Nov;172(22):5293-305. doi: 10.1111/bph.13315. Epub 2015 Oct 22.

15.

Innovative pharmaceutical interventions in cardiovascular disease: Focusing on the contribution of non-HDL-C/LDL-C-lowering versus HDL-C-raising: A systematic review and meta-analysis of relevant preclinical studies and clinical trials.

Kühnast S, Fiocco M, van der Hoorn JW, Princen HM, Jukema JW.

Eur J Pharmacol. 2015 Sep 15;763(Pt A):48-63. doi: 10.1016/j.ejphar.2015.03.089. Epub 2015 May 16. Review.

PMID:
25989133
16.

No effects of atorvastatin (10 mg/d or 80 mg/d) on nitric oxide, prostacyclin, thromboxane and oxidative stress in type 2 diabetes mellitus patients of the DALI study.

Tsikas D, Pham VV, Suchy MT, van de Ree MA, Huisman MV, Frölich JC, Princen HM; DALI-Study Group.

Pharmacol Res. 2015 Apr;94:1-8. doi: 10.1016/j.phrs.2015.01.004. Epub 2015 Feb 7.

PMID:
25662039
17.

PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE.

Ason B, van der Hoorn JW, Chan J, Lee E, Pieterman EJ, Nguyen KK, Di M, Shetterly S, Tang J, Yeh WC, Schwarz M, Jukema JW, Scott R, Wasserman SM, Princen HM, Jackson S.

J Lipid Res. 2014 Nov;55(11):2370-9. doi: 10.1194/jlr.M053207. Epub 2014 Sep 25.

18.

Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin.

Kühnast S, van der Tuin SJ, van der Hoorn JW, van Klinken JB, Simic B, Pieterman E, Havekes LM, Landmesser U, Lüscher TF, Willems van Dijk K, Rensen PC, Jukema JW, Princen HM.

Eur Heart J. 2015 Jan 1;36(1):39-48. doi: 10.1093/eurheartj/ehu319. Epub 2014 Aug 20.

19.

Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin.

Kühnast S, van der Hoorn JW, Pieterman EJ, van den Hoek AM, Sasiela WJ, Gusarova V, Peyman A, Schäfer HL, Schwahn U, Jukema JW, Princen HM.

J Lipid Res. 2014 Oct;55(10):2103-12. doi: 10.1194/jlr.M051326. Epub 2014 Aug 19.

20.

APOE*3Leiden.CETP transgenic mice as model for pharmaceutical treatment of the metabolic syndrome.

van den Hoek AM, van der Hoorn JW, Maas AC, van den Hoogen RM, van Nieuwkoop A, Droog S, Offerman EH, Pieterman EJ, Havekes LM, Princen HM.

Diabetes Obes Metab. 2014 Jun;16(6):537-44. doi: 10.1111/dom.12252. Epub 2014 Jan 16.

PMID:
24373179
21.

Metformin lowers plasma triglycerides by promoting VLDL-triglyceride clearance by brown adipose tissue in mice.

Geerling JJ, Boon MR, van der Zon GC, van den Berg SA, van den Hoek AM, Lombès M, Princen HM, Havekes LM, Rensen PC, Guigas B.

Diabetes. 2014 Mar;63(3):880-91. doi: 10.2337/db13-0194. Epub 2013 Nov 22.

22.

Niacin Reduces Atherosclerosis Development in APOE*3Leiden.CETP Mice Mainly by Reducing NonHDL-Cholesterol.

Kühnast S, Louwe MC, Heemskerk MM, Pieterman EJ, van Klinken JB, van den Berg SA, Smit JW, Havekes LM, Rensen PC, van der Hoorn JW, Princen HM, Jukema JW.

PLoS One. 2013 Jun 19;8(6):e66467. doi: 10.1371/journal.pone.0066467. Print 2013.

23.

Osteoarthritis development is induced by increased dietary cholesterol and can be inhibited by atorvastatin in APOE*3Leiden.CETP mice--a translational model for atherosclerosis.

Gierman LM, Kühnast S, Koudijs A, Pieterman EJ, Kloppenburg M, van Osch GJ, Stojanovic-Susulic V, Huizinga TW, Princen HM, Zuurmond AM.

Ann Rheum Dis. 2014 May;73(5):921-7. doi: 10.1136/annrheumdis-2013-203248. Epub 2013 Apr 26.

PMID:
23625977
24.

Colestilan decreases weight gain by enhanced NEFA incorporation in biliary lipids and fecal lipid excretion.

Sugimoto-Kawabata K, Shimada H, Sakai K, Suzuki K, Kelder T, Pieterman EJ, Cohen LH, Havekes LM, Princen HM, van den Hoek AM.

J Lipid Res. 2013 May;54(5):1255-64. doi: 10.1194/jlr.M032839. Epub 2013 Feb 22.

25.

Resveratrol protects against atherosclerosis, but does not add to the antiatherogenic effect of atorvastatin, in APOE*3-Leiden.CETP mice.

Berbée JF, Wong MC, Wang Y, van der Hoorn JW, Khedoe PP, van Klinken JB, Mol IM, Hiemstra PS, Tsikas D, Romijn JA, Havekes LM, Princen HM, Rensen PC.

J Nutr Biochem. 2013 Aug;24(8):1423-30. doi: 10.1016/j.jnutbio.2012.11.009. Epub 2013 Jan 18.

PMID:
23337345
26.

Niacin reduces plasma CETP levels by diminishing liver macrophage content in CETP transgenic mice.

Li Z, Wang Y, van der Sluis RJ, van der Hoorn JW, Princen HM, Van Eck M, Van Berkel TJ, Rensen PC, Hoekstra M.

Biochem Pharmacol. 2012 Sep 15;84(6):821-9. doi: 10.1016/j.bcp.2012.06.020. Epub 2012 Jun 27.

PMID:
22750059
27.

Distribution of perfluorooctanesulfonate and perfluorooctanoate into human plasma lipoprotein fractions.

Butenhoff JL, Pieterman E, Ehresman DJ, Gorman GS, Olsen GW, Chang SC, Princen HM.

Toxicol Lett. 2012 May 5;210(3):360-5. doi: 10.1016/j.toxlet.2012.02.013. Epub 2012 Feb 24.

PMID:
22387339
28.

Aliskiren inhibits atherosclerosis development and improves plaque stability in APOE*3Leiden.CETP transgenic mice with or without treatment with atorvastatin.

Kühnast S, van der Hoorn JW, van den Hoek AM, Havekes LM, Liau G, Jukema JW, Princen HM.

J Hypertens. 2012 Jan;30(1):107-16. doi: 10.1097/HJH.0b013e32834ddd8e.

PMID:
22134386
29.

Perfluoroalkyl sulfonates cause alkyl chain length-dependent hepatic steatosis and hypolipidemia mainly by impairing lipoprotein production in APOE*3-Leiden CETP mice.

Bijland S, Rensen PC, Pieterman EJ, Maas AC, van der Hoorn JW, van Erk MJ, Havekes LM, Willems van Dijk K, Chang SC, Ehresman DJ, Butenhoff JL, Princen HM.

Toxicol Sci. 2011 Sep;123(1):290-303. doi: 10.1093/toxsci/kfr142. Epub 2011 Jun 24.

PMID:
21705711
30.

Fenofibrate increases very low density lipoprotein triglyceride production despite reducing plasma triglyceride levels in APOE*3-Leiden.CETP mice.

Bijland S, Pieterman EJ, Maas AC, van der Hoorn JW, van Erk MJ, van Klinken JB, Havekes LM, van Dijk KW, Princen HM, Rensen PC.

J Biol Chem. 2010 Aug 13;285(33):25168-75. doi: 10.1074/jbc.M110.123992. Epub 2010 May 25.

31.

CETP does not affect triglyceride production or clearance in APOE*3-Leiden mice.

Bijland S, van den Berg SA, Voshol PJ, van den Hoek AM, Princen HM, Havekes LM, Rensen PC, Willems van Dijk K.

J Lipid Res. 2010 Jan;51(1):97-102. doi: 10.1194/jlr.M900186-JLR200.

32.

The dual PPARalpha/gamma agonist tesaglitazar blocks progression of pre-existing atherosclerosis in APOE*3Leiden.CETP transgenic mice.

van der Hoorn JW, Jukema JW, Havekes LM, Lundholm E, Camejo G, Rensen PC, Princen HM.

Br J Pharmacol. 2009 Apr;156(7):1067-75. doi: 10.1111/j.1476-5381.2008.00109.x. Epub 2009 Feb 13.

33.

PXR agonism decreases plasma HDL levels in ApoE3-Leiden.CETP mice.

de Haan W, de Vries-van der Weij J, Mol IM, Hoekstra M, Romijn JA, Jukema JW, Havekes LM, Princen HM, Rensen PC.

Biochim Biophys Acta. 2009 Mar;1791(3):191-7. doi: 10.1016/j.bbalip.2008.12.008. Epub 2008 Dec 25.

PMID:
19150509
34.

Bexarotene induces dyslipidemia by increased very low-density lipoprotein production and cholesteryl ester transfer protein-mediated reduction of high-density lipoprotein.

de Vries-van der Weij J, de Haan W, Hu L, Kuif M, Oei HL, van der Hoorn JW, Havekes LM, Princen HM, Romijn JA, Smit JW, Rensen PC.

Endocrinology. 2009 May;150(5):2368-75. doi: 10.1210/en.2008-1540. Epub 2009 Jan 15.

PMID:
19147676
35.

Preferential campesterol incorporation into various tissues in apolipoprotein E*3-Leiden mice consuming plant sterols or stanols.

Plat J, de Jong A, Volger OL, Princen HM, Mensink RP.

Metabolism. 2008 Sep;57(9):1241-7. doi: 10.1016/j.metabol.2008.04.018.

PMID:
18702950
36.

Negative effects of rofecoxib treatment on cardiac function after ischemia-reperfusion injury in APOE3Leiden mice are prevented by combined treatment with thromboxane prostanoid-receptor antagonist S18886 (terutroban).

van der Hoorn JW, Jukema JW, Bekkers ME, Princen HM, Corda S, Emeis JJ, Steendijk P.

Crit Care Med. 2008 Sep;36(9):2576-82. doi: 10.1097/CCM.0b013e318183f0fd.

PMID:
18679128
37.

Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden.CETP mice.

van der Hoorn JW, de Haan W, Berbée JF, Havekes LM, Jukema JW, Rensen PC, Princen HM.

Arterioscler Thromb Vasc Biol. 2008 Nov;28(11):2016-22. doi: 10.1161/ATVBAHA.108.171363. Epub 2008 Jul 31.

PMID:
18669886
38.

Torcetrapib does not reduce atherosclerosis beyond atorvastatin and induces more proinflammatory lesions than atorvastatin.

de Haan W, de Vries-van der Weij J, van der Hoorn JW, Gautier T, van der Hoogt CC, Westerterp M, Romijn JA, Jukema JW, Havekes LM, Princen HM, Rensen PC.

Circulation. 2008 May 13;117(19):2515-22. doi: 10.1161/CIRCULATIONAHA.107.761965. Epub 2008 May 5.

PMID:
18458167
39.

The impact of metabolic syndrome and CRP on vascular phenotype in type 2 diabetes mellitus.

Alizadeh Dehnavi R, Beishuizen ED, van de Ree MA, Le Cessie S, Huisman MV, Kluft C, Princen HM, Tamsma JT.

Eur J Intern Med. 2008 Mar;19(2):115-21. doi: 10.1016/j.ejim.2007.06.011. Epub 2007 Nov 5.

PMID:
18249307
40.

Olmesartan and pravastatin additively reduce development of atherosclerosis in APOE*3Leiden transgenic mice.

van der Hoorn JW, Kleemann R, Havekes LM, Kooistra T, Princen HM, Jukema JW.

J Hypertens. 2007 Dec;25(12):2454-62.

PMID:
17984667
41.

Atorvastatin increases HDL cholesterol by reducing CETP expression in cholesterol-fed APOE*3-Leiden.CETP mice.

de Haan W, van der Hoogt CC, Westerterp M, Hoekstra M, Dallinga-Thie GM, Princen HM, Romijn JA, Jukema JW, Havekes LM, Rensen PC.

Atherosclerosis. 2008 Mar;197(1):57-63. Epub 2007 Sep 14.

PMID:
17868678
42.

Mouse models for atherosclerosis and pharmaceutical modifiers.

Zadelaar S, Kleemann R, Verschuren L, de Vries-Van der Weij J, van der Hoorn J, Princen HM, Kooistra T.

Arterioscler Thromb Vasc Biol. 2007 Aug;27(8):1706-21. Epub 2007 May 31. Review.

PMID:
17541027
43.

Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression.

van der Hoogt CC, de Haan W, Westerterp M, Hoekstra M, Dallinga-Thie GM, Romijn JA, Princen HM, Jukema JW, Havekes LM, Rensen PC.

J Lipid Res. 2007 Aug;48(8):1763-71. Epub 2007 May 24.

44.

The cholesterol-raising factor from coffee beans, cafestol, as an agonist ligand for the farnesoid and pregnane X receptors.

Ricketts ML, Boekschoten MV, Kreeft AJ, Hooiveld GJ, Moen CJ, Müller M, Frants RR, Kasanmoentalib S, Post SM, Princen HM, Porter JG, Katan MB, Hofker MH, Moore DD.

Mol Endocrinol. 2007 Jul;21(7):1603-16. Epub 2007 Apr 24.

PMID:
17456796
45.

Plasma annexin A5 level relates inversely to the severity of coronary stenosis.

van Tits LJ, van Heerde WL, van der Vleuten GM, de Graaf J, Grobbee DE, van de Vijver LP, Stalenhoef AF, Princen HM.

Biochem Biophys Res Commun. 2007 May 11;356(3):674-80. Epub 2007 Mar 12.

PMID:
17374363
46.

Effect of garlic powder on C-reactive protein and plasma lipids in overweight and smoking subjects.

van Doorn MB, Espirito Santo SM, Meijer P, Kamerling IM, Schoemaker RC, Dirsch V, Vollmar A, Haffner T, Gebhardt R, Cohen AF, Princen HM, Burggraaf J.

Am J Clin Nutr. 2006 Dec;84(6):1324-9.

PMID:
17158412
47.

Cholesterol 7alpha-hydroxylase deficiency in mice on an APOE*3-Leiden background increases hepatic ABCA1 mRNA expression and HDL-cholesterol.

Post SM, Groenendijk M, van der Hoogt CC, Fievet C, Luc G, Hoekstra M, Princen HM, Staels B, Rensen PC.

Arterioscler Thromb Vasc Biol. 2006 Dec;26(12):2724-30. Epub 2006 Sep 28.

PMID:
17008588
48.

Fenofibrate reduces atherogenesis in ApoE*3Leiden mice: evidence for multiple antiatherogenic effects besides lowering plasma cholesterol.

Kooistra T, Verschuren L, de Vries-van der Weij J, Koenig W, Toet K, Princen HM, Kleemann R.

Arterioscler Thromb Vasc Biol. 2006 Oct;26(10):2322-30. Epub 2006 Jul 27.

PMID:
16873727
49.

Fish oil increases bile acid synthesis in male patients with hypertriglyceridemia.

Jonkers IJ, Smelt AH, Princen HM, Kuipers F, Romijn JA, Boverhof R, Masclee AA, Stellaard F.

J Nutr. 2006 Apr;136(4):987-91.

PMID:
16549462
50.

No effect of C-reactive protein on early atherosclerosis development in apolipoprotein E*3-leiden/human C-reactive protein transgenic mice.

Trion A, de Maat MP, Jukema JW, van der Laarse A, Maas MC, Offerman EH, Havekes LM, Szalai AJ, Princen HM, Emeis JJ.

Arterioscler Thromb Vasc Biol. 2005 Aug;25(8):1635-40. Epub 2005 May 26.

PMID:
15920036

Supplemental Content

Loading ...
Support Center